Abstract 349P
Background
Euphorbia hirta has many health benefits for enhancing human health. It exhibits various antioxidant properties. Our aim was to investigate the effects of several polyphenols from Euphorbia hirta ethanolic extract on the growth and metastatic potential of B16F10 melanoma cells in vitro and to measure the observable changes of cell morphology upon exposure to the extract.
Methods
The cytotoxic activity of the Euphorbia hirta extract on B16F10 melanoma cell line was investigated in vitro using 3‐ (4, 5‐dimethyl thiazol‐2yl) ‐2, 5‐diphenyl tetrazolium bromide (MTT). B16F10 (human Melanoma) cell lines were cultured in DMEM supplemented with 10% inactivated Fetal Bovine Serum (FBS), penicillin (100 IU/ml), streptomycin (100 μg/ml) and amphotericin B (5 μg/ml) in an humidified atmosphere of 5% CO2 at 37 °C until confluent. The cells were dissociated with Trypsin solution (0.2% trypsin, 0.02% EDTA in PBS). The stock cultures were grown in 25 cm2 culture flasks and all experiments were carried out in 96 micro-titer plates. After culturing and proliferation of B16F10 cells, these cells were exposed to various ethanolic extract of E hirta. The potency of plant extract concentration was calculated in terms of a percent decrease in viable B16F10 cells as compared to the control value.
Results
The in vitro growth of B16F10 melanoma cells in the presence of a series of polyphenolic compounds (10–9 to 10–5 M) was evaluated. Quercetin, apigenin, EGCG, resveratrol, curcumin, and tamoxifen inhibited the growth of B16F10 cells in a concentration‐dependent manner. The concentrations needed to inhibit cell growth by 50% (IC50) are reported. The results of MTT assay test showed that the ethanol extract of Euphorbia hirta was tested for the anticancer activity and it showed the most effective inhibition of B16F10 cells proliferation.
Conclusions
We assessed the cytotoxic effect of Euphorbia hirta extract in cell culture. In defiance of astonishing advances in modern medicine, such as surgery, radiotherapy, chemotherapy, and immunotherapy, melanoma cancer disease remains a worldwide health problem, thus endeavoring the search for a new alternate approach.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
164P - Multi-centered phase II trial of weekly 5-FU plus l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant advanced gastric cancer (HGCSG1502)
Presenter: Yusuke Sasaki
Session: Poster display session
Resources:
Abstract
165P - Lenvatinib treatment for advanced hepatocellular carcinoma: The relationship between efficacy and safety
Presenter: Takayoshi Oikawa
Session: Poster display session
Resources:
Abstract
166P - The comparison between UGT1A1 single heterozygous and wild type regarding the clinical outcomes of fixed dose irinotecan monotherapy for advanced gastric cancer: Multicenter retrospective study
Presenter: Takahide Sasaki
Session: Poster display session
Resources:
Abstract
167P - Prognostic impact of the C-reactive protein/albumin ratio in advanced pancreatic cancer treated with GEM plus nab-PTX or FOLFIRINOX: Based on the results of a multicenter retrospective study (the NAPOLEON study)
Presenter: Akitaka Makiyama
Session: Poster display session
Resources:
Abstract
168P - A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of Glasgow Prognostic Score (GPS)
Presenter: Takuya Honda
Session: Poster display session
Resources:
Abstract
169P - M-phase phosphoprotein 8 promotes gastric cancer growth and metastasis via p53/Bcl-2 and EMT-related signalling pathways
Presenter: Yizhuo Wang
Session: Poster display session
Resources:
Abstract
170P - Surgery alone versus surgery combined with Chemotherapy: Survival patterns among patients with fibrolamellar hepatocellular carcinoma
Presenter: Yasmine Ashraf
Session: Poster display session
Resources:
Abstract
171P - The clinical value of prognostic nutritional index in patients with anastomotic leakage after minimally invasive esophagectomy
Presenter: Yan Wang
Session: Poster display session
Resources:
Abstract
172P - Preoperative neutrophil‐to‐lymphocyte ratio (NLR) predicts recurrence after surgery in patient with pancreatic neuroendocrine neoplasm (PanNEN)
Presenter: Takayuki Miura
Session: Poster display session
Resources:
Abstract
173P - Cancer stem-like phenotypes including immune surveillance and its responsible genes in induced liver cancer stem-like cells
Presenter: Ryouichi Tsunedomi
Session: Poster display session
Resources:
Abstract